Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan

Szu-Heng Wang1,2☯, Dong-Yi Chen2,3☯, Yu-Sheng Lin2,4, Chun-Tai Mao2,5, Ming-Lung Tsai2,3, Ming-Jer Hsieh2,3, Chung-Chuan Chou2,3, Ming-Shien Wen2,3, Chun-Chieh Wang2,3, I-Chang Hsieh2,3, Kuo-Chun Hung2,3, Tien-Hsing Chen2,3,6 *

1 Department of Medical education, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 2 College of Medicine, Chang Gung University, Taoyuan, Taiwan, 3 Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 4 Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan, 5 Heart Failure Center, Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan, 6 Department of cardiology, Chang Gung Memorial Hospital, Xiamen, China

☯ These authors contributed equally to this work.
* skyheart0826@gmail.com

Abstract

Background
The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients after acute myocardial infarction (AMI) has so far remained uncertain.

Methods
We analyzed data from the National Health Insurance Research Database (NHIRD), a government-operated, population-based database, from March 1st, 2009 to December 31st, 2011. Type 2 diabetic patients hospitalized for AMI were included in our study. We compared subjects using sitagliptin with comparison group to evaluate its cardiovascular safety and efficacy. The primary endpoint was a composite of cardiovascular death, myocardial infarction, and ischemic stroke.

Results
We identified a total of 3,282 type 2 diabetic patients hospitalized for AMI (mean follow-up 1.15 years). Of these patients, 547 (16.7%) who were exposed to sitagliptin were defined as the sitagliptin group and 2,735 (83.3 %) who did not use sitagliptin were the comparison group. The incidence of primary composite cardiovascular outcomes was 9.50 per 100 person-years in the sitagliptin group and was 9.70 per 100 person-years in the comparison group (hazard ratio (HR), 0.97; 95% CI, 0.73–1.29, P=0.849). Compared to the non-sitagliptin group, the sitagliptin group had similar risks of all-cause mortality, hospitalization for...
heart failure (HF) or percutaneous coronary intervention (PCI) with a HR of 0.82 (95% CI, 0.61–1.11, P=0.195), 0.93 (95% CI, 0.67–1.29, P=0.660), and 0.93 (95% CI, 0.75–1.14, P=0.473), respectively.

Conclusion
The use of sitagliptin in type 2 diabetic patients with recent AMI was not associated with increased risk of adverse cardiovascular events.

Introduction
Type 2 diabetes mellitus (T2DM) is associated with elevated risk of cardiovascular disease; more than half of patients with diabetes die of cardiovascular complications [1,2]. Diabetic patients who have yet to develop myocardial infarction have comparable cardiovascular risk to that of non-diabetic patients with a prior myocardial infarction. Diabetic patients who have a history of myocardial infarction are at an even higher risk, with a seven-year AMI incidence of 45% [3]. Improved glycemic control has been shown to reduce the risk of microvascular complications of T2DM, but studies have failed to demonstrate that glycemic control reduces the risk of macrovascular events [4–6]. Concerns about adverse cardiovascular events with antidiabetic agents indicate a clinical need to identify the cardiovascular safety and benefit of antihyperglycemic agents [7,8].

Sitagliptin is an orally administered dipeptidyl peptidase-4 (DPP-4) inhibitor that exerts antihyperglycemic effects by increasing the availability of incretin hormones, which in turn modulates pancreatic islet hormone secretion [9,10]. Some studies have revealed a decreased risk of adverse cardiovascular events in DPP-4-treated subjects [11] whereas others suggest a neutral effect on cardiovascular events [12–14]. Moreover, results from observational studies have shown that sitagliptin may increase cardiovascular risk [15], especially in patients with chronic kidney disease [16]. As a result, there remains much speculation about the cardiovascular benefit and potential risks of this medication.

This nationwide, prospective cohort study aimed to examine sitagliptin use and cardiovascular outcomes in patients with T2DM after AMI. Secondary safety outcomes were also considered.

Methods
Data Source
We conducted this nationwide population-based cohort study using Taiwan’s National Health Insurance Research Database (NHIRD), a government-operated, population-based database derived from the claims data of Taiwan’s National Health Insurance program, covering 99.19% of the population [17]. The NHIRD database provides comprehensive and accurate records of beneficiaries, including ambulatory visits, inpatient care, disease diagnosis codes, and medication prescriptions. The accuracy and validity of NHIRD data has been previously confirmed [18–20]. The Ethics Institutional Review Board of Chang Gung Memorial Hospital approved the study.

Study Population
Patients with a diagnosis of type 2 diabetes (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 250.xx) were included in this study. We identified
patients who were hospitalized for AMI (ICD-9-CM code 410.xx) between March 1st, 2009 and December 31st, 2011. The index hospitalization was defined as the date on which patient was admitted for AMI. Patients’ baseline characteristics, such as gender and age, were considered. We also identified baseline comorbidities, medication prescription, and previous medical procedures, such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG).

Patients were excluded if they met any of the following criteria. (Fig 1): (1) age < 40 years; (2) expired during index hospitalization for AMI; (3) received sitagliptin treatment before index hospitalization; (4) use of thiazolidinediones or other DPP-4 inhibitors; (5) received renal replacement therapies; (6) developed a composite primary cardiovascular endpoint (defined as death, AMI or ischemic stroke) within 30 days of discharge; (7) were followed for less than 30 days after the index hospitalization; and (8) was diagnosed with T2DM during index hospitalization (defined as patient who did not use antihyperglycemic agents prior to index hospitalization).

**Exposure to Sitagliptin and Concomitant Medications**

Sitagliptin exposure was based on computer-based prescription claims after the index hospitalization. We defined patients who received a prescription of sitagliptin for 90 consecutive days following index discharge as the sitagliptin group, while those who did not receive sitagliptin were considered the comparison cohort. Sitagliptin dosages were prescribed according to Taiwan’s National Health Insurance regulations, which were 100mg, 50mg and 25mg daily for patients with an estimated glomerular filtration rate (eGFR) of over 50 ml/min, between 30 to 50 ml/min and below 30 ml/min, respectively. We used NHIRD claims data from ambulatory visits to obtain data on concomitant medication use in each patient. The following pharmaceutical agents were considered: metformin, sulfonylurea, insulin, angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers, aspirin, antiplatelets, calcium channel blockers, diuretics and statins.
Study Endpoints and Covariates

Baseline comorbidities were identified by ICD-9-CM diagnosis codes and medications during index hospitalization (see S1 Table). We defined primary outcomes as composite events of cardiovascular death, myocardial infarction or ischemic stroke. The definition of cardiovascular death met the criteria of the Standardized Definitions for End Point Events in Cardiovascular Trials draft by the United States Food and Drug Administration [21]. Death and causes of death were collected from registry data of the NHIRD [22]. Other secondary outcomes of interest were death by any cause, hospitalization for heart failure, coronary revascularization, pancreatitis, hypoglycemia and diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS).

Statistical Analysis

Propensity score matching (PSM) was used to reduce potential confounding and selection biases because patients in this study were not randomly assigned to treatment with sitagliptin [23]. The sitagliptin cohort was matched with the comparison cohort according to a 1:5 ratio in terms of patient’s characteristics, baseline comorbidities, medication prescribed 90 days since index hospitalization (listed in Tables 1 and 2), and index year and month using the PSM method. The PSM matching algorithm was based on the nearest-neighbor method in which the treated and control subjects were randomly ordered according to the estimated propensity score, then the first treated subject was selected and the corresponding control subject(s) were found and matched with the closest propensity score. In addition, the PSM matching was performed with the caliper radius, which the control subjects within a predefined amount of the estimated propensity score (set as 0.5 sigma) are selected and matched [24]. The matching procedure was performed with SAS Version 9.3 (SAS Institute, Cary, NC).

Table 1. Baseline clinical characteristics of the study patients.

| Characteristics                  | Sitagliptin (n = 547) | Comparison (n = 2,735) | P    |
|----------------------------------|-----------------------|------------------------|------|
| Age, year                        | 66.0±12.2             | 65.9±12.1              | 0.911|
| Age ≥75 years                    | 149 (27.2)            | 725 (26.5)             | 0.724|
| Gender                           |                       |                        | 0.909|
| Male                             | 350 (64.0)            | 1,743 (63.7)           |      |
| Female                           | 197 (36.0)            | 992 (36.3)             |      |
| Previous myocardial infarction   | 20 (3.7)              | 108 (3.9)              | 0.747|
| Previous cerebral vascular accident| 73 (13.3)            | 341 (12.5)             | 0.573|
| Comorbidity                      |                       |                        |      |
| Coronary artery disease          | 413 (75.5)            | 2,069 (75.6)           | 0.942|
| Chronic kidney disease           | 48 (8.8)              | 232 (8.5)              | 0.823|
| Peripheral arterial disease      | 27 (4.9)              | 137 (5.0)              | 0.943|
| Hypertension                     | 411 (75.1)            | 2,076 (75.9)           | 0.702|
| Heart failure                    | 181 (33.1)            | 920 (33.6)             | 0.804|
| Dyslipidemia                     | 335 (61.2)            | 1,703 (62.3)           | 0.652|
| Previous PCI                     | 367 (67.1)            | 1,844 (67.4)           | 0.881|
| Previous CABG                    | 4 (0.7)               | 18 (0.7)               | 0.848|
| Follow-up days                   | 422.2±263.0           | 418.7±274.1            | 0.783|
| Propensity score, %              | 7.3±3.7               | 7.3±3.6                | 0.784|

Values are mean ± SD or n (%); PCI = percutaneous coronary intervention; CABG = coronary artery bypass grafting.
We compared clinical characteristics between study groups (sitagliptin and comparison groups) by chi-square test for categorical variables and by independent sample t-test for continuous variables. We used Cox proportional hazards models to compare time to first occurrence of a predefined primary or secondary outcome following index hospitalization between study groups, adjusting the propensity score. We estimated the survival rates of a predefined period (i.e. three months and one year) for each study group, depicted with the Kaplan-Meier method. On the other hand, we reported the incidence density (per 100 person-years) as to the event at the complete course. All data analysis was conducted using IBM SPSS software version 22 (IBM SPSS Inc, Chicago, Illinois).

Results

Study Population

A total of 3,282 patients with type 2 diabetes who were hospitalized for AMI between March 2009 and December 2011 were identified for the study cohort. Of these patients, 547 (16.7%) were in the Sitagliptin group and 2,735 (83.3%) matched subjects were in the comparison group. The mean age for the overall cohort was 65.9 years (SD = 12.1 years). The mean follow-up period was 1.15 years (SD = 0.75 years), and the maximum follow-up time was 2.84 years. The two study groups were well matched with respect to baseline characteristics, comorbidities, follow-up period and concomitant medications.

Cardiovascular Outcomes

The incidence of composite primary cardiovascular outcome was 9.50 per 100 person-years in the Sitagliptin group and 9.70 per 100 person-years in the comparison group (HR = 0.97; 95% CI, 0.73–1.29, P = 0.849) (Fig 2). The risk of recurrent myocardial infarction (HR = 1.07; 95% CI, 0.72–1.59, P = 0.738), ischemic stroke (HR = 1.30; 95% CI, 0.75–2.26, P = 0.346) or cardiovascular death (HR = 0.65, CI, 0.39–1.10 P = 0.108) was similar for the two study groups (Table 3).

As for secondary outcomes, the sitagliptin group had similar risks of all-cause mortality, hospitalization for heart failure (HF), or percutaneous coronary revascularization with an HR of 0.82 (95% CI, 0.61–1.11, P = 0.195), 0.93 (95% CI, 0.67–1.29, P = 0.660), and 0.93 (95% CI, 0.75–1.14, P = 0.473) respectively, compared to the non-sitagliptin group (Fig 3). Subgroup analysis revealed that sitagliptin use was not associated with increased risk of heart failure.
hospitalization in patients with previous history of heart failure (HR = 1.05; 95% CI, 0.71–1.56, P = 0.809) or without it (HR = 0.73; 95% CI, 0.40–1.33, P = 0.304).

**Safety Outcomes**

The sitagliptin and non-sitagliptin groups did not differ significantly with respect to incidence of hyperglycemia complications (0.95 and 0.54 per 100 person-years, HR = 1.78; 95% CI, 0.70–4.50, P = 0.227). The incidence of hypoglycemia was also similar across the two study groups (1.44 and 1.19 per 100 person-years; HR = 1.22; 95% CI, 0.59–2.52, P = 0.597). There were no significant differences in the incidence of pancreatitis between the two groups (Table 4).

**Discussion**

In this population-based cohort study, we demonstrate that sitagliptin use was not associated with increased risk of primary composite cardiovascular outcomes among AMI patients, when compared to subjects who did not use sitagliptin. Analysis of individual components of the primary cardiovascular outcomes (AMI, ischemic stroke, and cardiovascular death) found no significant difference between these two groups at one-year and all-course follow up. Secondary outcome analysis demonstrated that the sitagliptin and comparison groups had a similar incidence of heart failure hospitalization, pancreatitis, hypoglycemia episodes and complications of hyperglycemia. The two groups also had similar likelihood of receiving a subsequent percutaneous coronary revascularization. To date, the cardiovascular effects of DPP-IV inhibitors...
have not been confirmed; our results suggest sitagliptin use is not associated with increased cardiovascular risks.

Our study aimed to evaluate the safety profile of sitagliptin in AMI patients on a population-based, nationwide scale. Compared with other studies [12,13], we examined only subjects who had a recent episode of myocardial infarction hospitalization, making our cohort at a much higher risk than patients in other studies. With a mean follow-up period of 14 months, 10% of our study subjects developed a primary endpoint, making our results invaluable for patients who are at high risk for adverse cardiovascular events. Researchers from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial reported a primary endpoint rate of more than 11%, but found no increased risk associated with alogliptin use when compared to placebo in patients with recent AMI or unstable angina [25]. Our results are in agreement with those of the EXAMINE trial, suggesting that DPP-IV inhibitors are safe for patients who have a high risk of adverse cardiovascular events. Notably, the sitagliptin group in our study had a reduced rate of cardiovascular death at three-month follow up, but not at one-year and all-course follow up (Table 3). Due to the nature of multiple testing and the possibility of type one error, the protective effect shown here should be interpreted with caution. Further research is warranted to elucidate this potentially beneficial effect.

Previous study from our group has indicated an association between sitagliptin use and increased risks of recurrent AMI and percutaneous coronary revascularization among type 2 diabetic patients with chronic kidney disease after AMI, especially in the end-stage renal disease subgroup [16]. The seemingly opposite conclusion reached by our previous paper is likely the result of difference in study population, in which all subjects had kidney function impairment and more than half diagnosed with end-stage renal disease. On the other hand, subjects with chronic kidney disease accounted for only 8% of the study cohort in the present study, and patients with end-stage renal disease were excluded. The drastic difference in renal

---

Table 3. Primary outcomes in various follow up periods.

| Outcome                    | Number of event (%)‡ | Sitagliptin vs. Comparison | P     |
|----------------------------|----------------------|---------------------------|-------|
|                            | Sitagliptin          | Comparison                | HR (95% CI)† |
|                            |                      |                           |       |
| **3 month follow up**      |                      |                           |       |
| Myocardial infarction      | 10 (1.8)             | 53 (1.9)                  | 0.94 (0.48–1.84) | 0.851 |
| Ischemic stroke            | 5 (0.9)              | 15 (0.5)                  | 1.67 (0.61–4.59) | 0.322 |
| Cardiovascular death       | 2 (0.4)              | 45 (1.6)                  | 0.22 (0.05–0.91) | 0.037 |
| Primary endpoint§          | 16 (2.9)             | 108 (3.9)                 | 0.74 (0.44–1.25) | 0.262 |
| **1 year follow up**       |                      |                           |       |
| Myocardial infarction      | 26 (4.8)             | 116 (4.2)                 | 1.11 (0.72–1.69) | 0.642 |
| Ischemic stroke            | 12 (2.2)             | 44 (1.6)                  | 1.35 (0.71–2.55) | 0.360 |
| Cardiovascular death       | 10 (1.8)             | 91 (3.3)                  | 0.54 (0.28–1.04) | 0.066 |
| Primary endpoint§          | 45 (8.2)             | 233 (8.5)                 | 0.96 (0.70–1.32) | 0.802 |
| **All course**             |                      |                           |       |
| Myocardial infarction      | 4.95                 | 4.61                      | 1.07 (0.72–1.59) | 0.738 |
| Ischemic stroke            | 2.60                 | 1.98                      | 1.30 (0.75–2.26) | 0.346 |
| Cardiovascular death       | 2.53                 | 3.89                      | 0.65 (0.39–1.10) | 0.108 |
| Primary endpoint§          | 9.50                 | 9.70                      | 0.97 (0.73–1.29) | 0.849 |

† adjusted for propensity score
§ anyone of myocardial infarction, ischemic stroke, or cardiovascular death
‡ Number of events per 100 person-years during the all-course follow-up

doi:10.1371/journal.pone.0131122.t003

---
function and other clinical characteristics may explain such contrasting results from the two studies.

Our results suggest that the use of sitagliptin was not associated with an increased incidence of heart failure hospitalization in the overall cohort, whether in patients with or without previous history of CHF. So far, a causal relationship between DPP-4 inhibitors and CHF has not been established. The recent SAVOR trial found an increased likelihood of hospitalization for heart failure in the Saxagliptin group [14,26]. Moreover, in a retrospective study using data from a U.S. commercial insurance claims database, Weir and colleagues showed that sitagliptin is associated with an increased risk of heart failure hospitalization in diabetic patients with incident heart failure [15]. Unlike the retrospective study conducted by Weir et. al., our research

Fig 3. Cumulative Kaplan-Meier survival estimates of the time to individual components of the primary composite endpoint and heart failure hospitalization. The sitagliptin and comparison groups had similar incidence of individual components of the primary composite endpoint, such as AMI (Panel A), ischemic stroke (Panel B), cardiovascular death (Panel C), and hospitalization for heart failure (Panel D).

doi:10.1371/journal.pone.0131122.g003
employed a prospective approach, enrolling patients who had a recent AMI, with well-matched baseline characteristics between groups, and a stricter definition of sitagliptin use that required patients to receive 90 consecutive days of treatment. With this rigorous study design, our results certainly provide a strong piece of evidence to the current research field.

In light of the controversy surrounding the safety of DPP-4 inhibitors, a well-designed, randomized double-blinded clinical trial is needed. The Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) is an ongoing multinational clinical trial aiming to evaluate the efficacy of sitagliptin for reducing cardiovascular risk in patients with type 2 diabetes who have documented vascular disease in the coronary, cerebral, or peripheral arteries [27]. Although the TECOS trials enrolled patients who were at elevated cardiovascular risk, our study is unique in that only subjects who suffered a recent AMI were included. Therefore, our study provides an important source for evaluating sitagliptin safety in post AMI patients.

Our study has several strengths, including our prospective study design in which all patients who developed AMI were included and their outcomes analyzed. Moreover, after adjustment by propensity scoring, the sitagliptin and comparison groups are well matched in clinical characteristic. Lastly, we included only diabetic patients with recent AMI, who are at very high cardiovascular risk, making our study an invaluable source in this area of clinical research.

### Study Limitations

Our study has several limitations. First, the common confoundings of patient information were absent in our study, such as family history of cardiovascular disease, smoking, body mass index, or lipid profile. The two patient groups may differ in unmeasured ways. To avoid this bias, we utilized propensity score to balance every clinical characteristics between the two cohorts. We adapted the strictest enrollment criteria enrollment, which only included patients with acute myocardial infarction to ensure very-high cardiovascular risks existing between sitagliptin group and comparison group. We believe the methodologies used in this study are valid. Second, coding error may exist in a database. Our study based its patient enrollment and

### Table 4. Secondary outcomes (all course).

| Outcome                                      | Number of event‡ | Sitagliptin vs. Comparison |
|----------------------------------------------|------------------|---------------------------|
|                                              | Sitagliptin      | Comparison                | HR (95% CI)† | P      |
| **Other cardiovascular outcomes**            |                  |                           |              |        |
| Non-fatal myocardial infarction              | 4.62             | 4.11                      | 1.12 (0.74–1.68) | 0.598 |
| Non-fatal ischemic stroke                    | 2.44             | 1.94                      | 1.24 (0.71–2.19) | 0.453 |
| Death from any cause                         | 7.74             | 9.50                      | 0.82 (0.61–1.11) | 0.195 |
| Heart failure                                | 7.07             | 7.63                      | 0.93 (0.67–1.29) | 0.660 |
| Percutaneous coronary revascularization      | 19.56            | 21.36                     | 0.93 (0.75–1.14) | 0.473 |
| **Safety outcomes**                          |                  |                           |              |        |
| Any pancreatitis                             | 0.16             | 0.26                      | 0.61 (0.08–4.87) | 0.640 |
| Acute pancreatitis                           | 0.16             | 0.26                      | 0.61 (0.08–4.87) | 0.640 |
| Chronic pancreatitis                         | 0                | 0                         | NA           | NA     |
| Hypoglycemia                                 | 1.44             | 1.19                      | 1.22 (0.59–2.52) | 0.597 |
| DKA, HHS                                     | 0.95             | 0.54                      | 1.78 (0.70–4.50) | 0.227 |

† adjusted for propensity score; NA = not applicable; DKA = diabetic ketoacidosis; HHS = Hyperosmolar hyperglycemic state; NA = not applicable due to no event was observed
‡ Per 100 person-years

doi:10.1371/journal.pone.0131122.t004
outcome measurement on NHIRD in-patient diagnosis codes. Since these diagnoses were related to insurance reimbursement, its accuracy is regularly audited by the NHI Bureau. False reimbursement claims would result in substantial penalties, making coding errors less likely to take place. The accuracy and validity of NHIRD data were also confirmed by previous study [18–20]. Third, due to the fact that sitagliptin was not available in Taiwan until March 1st, 2009, our study has a mean follow-up period of 14 months, and trials of longer duration may be needed to study long-term outcomes. This limitation also prevents us from tracking long-term patient history such as duration of diabetes. However, recurrent adverse cardiovascular events are more likely to take place within 1 year after AMI than in other time frames. The duration of this study should be sufficient to analyze association between sitagliptin use and cardiovascular outcomes [28]. Finally, our study is based on the assumption that patients are completely compliant with physician’s orders.

**Conclusion**

In conclusion, this nationwide, population-based cohort study demonstrated that in type 2 diabetes patients with recent myocardial infarction, the use of sitagliptin is not associated with increased risk of composite adverse cardiovascular outcomes, including myocardial infarction, ischemic stroke, and cardiovascular death. Sitagliptin did not increase the risk of heart failure hospitalization, either. Our results can be used to help guide clinicians in formulating an optimal therapy for diabetic patients at very high risk of adverse cardiovascular events.

**Supporting Information**

S1 Table. ICD-9-CM code used for diagnosis in the current study.

(Word document)

**Acknowledgments**

We thank Hsing-Fen Lin for the statistical assistance.

**Author Contributions**

Conceived and designed the experiments: SHW DYC THC. Performed the experiments: SHW DYC THC. Analyzed the data: SHW DYC THC. Contributed reagents/materials/analysis tools: YSL CTM MLT MJH CCC MSW CCW ICH KCH. Wrote the paper: SHW DYC.

**References**

1. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. Journal of internal medicine. 2001; 248(3):225–35. PMID: 11285042

2. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia. 2001; 44 Suppl 2:S14–21. PMID: 11587045

3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339(4):229–34. PMID: 97429916

4. Group AC, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560–72. doi:10.1056/NEJMoa0802987 PMID: 18539916

5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837–53. PMID: 9742976
6. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360(2):129–39. doi: 10.1056/NEJMoa0808431 PMID: 19092145

7. Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med. 2008; 359(11):1092–5. doi: 10.1056/NEJMmp0805758 PMID: 18784098

8. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: Food and Drug Administration, 2008. Available: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071627.pdf?utm_campaign=Google2utm_source=fdaSearchutm_medium=websiteutm_term=guidance. Accessed July 15, 2014.

9. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diabetes & vascular disease research: official journal of the International Society of Diabetes and Vascular Disease. 2012; 9(2):109–16.

10. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Current medical research and opinion. 2007; 23(4):919–31. PMID: 17407649

11. Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012; 110(6):826–33. doi: 10.1016/j.amjcard.2012.04.061 PMID: 22703861

12. Scheller NM, Mogensen UM, Andersson C, Vaag A, Torp-Pedersen C. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population. Diabetes, obesity & metabolism. 2014; 16(3):231–6.

13. Engel SS, Goml GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovascular diabetology. 2013; 12:3. doi: 10.1186/1475-2840-12-3 PMID: 23286208

14. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. JAMA. 2012; 308(18):1906–14. doi:10.1001/jama.2012.255628

15. Weir DL, McAlister FA, Senthilvelan A, Minhas-Sandhu JK, Eurch DT. Sitaagliptin Use in Patients With Diabetes and Heart Failure: A Population-Based Retrospective Cohort Study. JACC Heart failure. 2014.

16. Chen DY, Wang SH, Mao CT, Tsai ML, Lin YS, Chou CC, et al. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study. Int J Cardiol. 2015; 181:200–6. doi: 10.1016/j.ijcard.2014.12.029 PMID: 25528312

17. National Health Insurance Research Database, Taiwan. (Accessed July 15, 2014) at http://nhird.nhri.org.tw/en/index.htm

18. Cheng CL, Lee CH, Chen PS, Li YH, Lin SJ, Yang YH. Validation of acute myocardial infarction cases in the national health insurance research database in taiwan. Journal of epidemiology / Japan Epidemiological Association. 2014; 24(6):500–7.

19. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiology and drug safety. 2011; 20(3):236–42. doi: 10.1002/pds.2087 PMID: 21351304

20. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY (2005) Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc 104: 157–63. PMID: 15818428

21. Administration, F.a.D., Standardized Definitions for End Point Events in Cardiovascular Trials. 2010: p. 37.

22. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012; 308(18):1906–14. PMID: 23162861

23. Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol, 2010; 172(9):1092–7. doi: 10.1093/aje/kwq224 PMID: 20802241

24. d’Agostino RB. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17(19):2265–2281. PMID: 9802183

25. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369(14):1327–35. doi: 10.1056/NEJMoa1303589 PMID: 23992602

26. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014; 130(18):1579–88. doi: 10.1161/CIRCULATIONAHA.114.010389 PMID: 25189213
27. Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. American heart journal. 2013; 166(6):983–9 e7. doi: 10.1016/j.ahj.2013.09.003 PMID: 24268212

28. Nakatani D, Sakata Y, Suna S, Usami M, Matsumoto S, Shimizu M, et al. Incidence, predictors, and subsequent mortality risk of recurrent myocardial infarction in patients following discharge for acute myocardial infarction. Circulation journal: official journal of the Japanese Circulation Society. 2013; 77(2):439–46.